Welcome to our dedicated page for Brainsway SEC filings (Ticker: BRSYF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BrainsWay Ltd. files as a foreign private issuer on Form 6-K, with reports incorporated by reference into its Form S-8 and Form F-3 registration statements. The filings document company updates on Deep TMS and transcranial magnetic stimulation therapy, U.S. reimbursement and payer coverage policies, and strategic investments related to mental health treatment providers and neurostimulation technologies.
The company's filed exhibits also include investor presentation materials and risk-factor discussion covering reimbursement, third-party payor decisions, healthcare regulation, manufacturing, market adoption, competition, product liability, and regulatory actions. These disclosures frame BrainsWay's registration statements, equity incentive registration, and ongoing current-report updates as an Israel-based issuer reporting on Form 20-F.
Brainsway Ltd. director Michal Ety Mitrany Rayten reported open-market sales of a total of 17,980 Ordinary Shares over two days. The shares were sold at prices of NIS 45.5588 and NIS 44.7516 per share. Following these transactions, she holds 12,500 Ordinary Shares, including 6,250 unvested RSUs that vest quarterly until March 5, 2028. The Ordinary Shares may also be held as American Depositary Shares, each currently representing one Ordinary Share.
Brainsway Ltd. director Michal Ety Mitrany Rayten reported open-market sales of a total of 17,980 Ordinary Shares over two days. The shares were sold at prices of NIS 45.5588 and NIS 44.7516 per share. Following these transactions, she holds 12,500 Ordinary Shares, including 6,250 unvested RSUs that vest quarterly until March 5, 2028. The Ordinary Shares may also be held as American Depositary Shares, each currently representing one Ordinary Share.
Brainsway Ltd. director Mitrany Rayten Michal Ety exercised stock options for 27,500 Ordinary Shares and settled related taxes with shares. On May 19–20, 2026, 27,500 options with an exercise price of NIS 15.26 per share were exercised, while 9,520 Ordinary Shares were retained by the company at NIS 44.36 and NIS 43.92 per share to cover the exercise price and tax liabilities.
Following these transactions, the director holds 30,480 Ordinary Shares directly, a figure that includes unvested RSUs for 6,250 shares that vest quarterly until March 5, 2028. The Ordinary Shares may also be represented by American Depositary Shares, each currently equal to one Ordinary Share. The filing reflects routine compensation-related activity rather than open‑market buying or selling.
Brainsway Ltd. director Mitrany Rayten Michal Ety exercised stock options for 27,500 Ordinary Shares and settled related taxes with shares. On May 19–20, 2026, 27,500 options with an exercise price of NIS 15.26 per share were exercised, while 9,520 Ordinary Shares were retained by the company at NIS 44.36 and NIS 43.92 per share to cover the exercise price and tax liabilities.
Following these transactions, the director holds 30,480 Ordinary Shares directly, a figure that includes unvested RSUs for 6,250 shares that vest quarterly until March 5, 2028. The Ordinary Shares may also be represented by American Depositary Shares, each currently equal to one Ordinary Share. The filing reflects routine compensation-related activity rather than open‑market buying or selling.
BrainsWay Ltd. reported a strategic equity investment in Hopemark Health, a mental health clinic platform in the greater Chicago area. BrainsWay will invest $1.5 million initially, with potential for an additional $1.5 million through milestone-based investments, in a minority preferred, annually compounding security with a redemption mechanism.
The partnership aligns with BrainsWay’s strategy of taking minority stakes in North American mental health providers to expand access to its Deep TMS neurostimulation treatments and raise awareness of advanced interventional psychiatry solutions, while allowing BrainsWay to remain focused on advancing its core business and technology.
BrainsWay Ltd. reported a strategic equity investment in Hopemark Health, a mental health clinic platform in the greater Chicago area. BrainsWay will invest $1.5 million initially, with potential for an additional $1.5 million through milestone-based investments, in a minority preferred, annually compounding security with a redemption mechanism.
The partnership aligns with BrainsWay’s strategy of taking minority stakes in North American mental health providers to expand access to its Deep TMS neurostimulation treatments and raise awareness of advanced interventional psychiatry solutions, while allowing BrainsWay to remain focused on advancing its core business and technology.
BrainsWay Ltd. reported strong Q1 2026 growth and profitability while emphasizing its shift to a high-margin recurring revenue model. Q1 2026 revenue rose 35% year over year to about $15.5 million, with net income more than doubling to roughly $2.3 million and Adjusted EBITDA up 117% to about $2.8 million.
The company shipped a record 117 Deep TMS systems in the quarter, expanding its installed base to roughly 1,820 systems and supporting an ARR-focused lease and pay-per-use model. Remaining performance obligations reached about $75 million and cash was $58 million as of March 31, 2026, with no debt.
BrainsWay reiterated full-year 2026 guidance for revenue of $66–68 million, operating income margin of 13–14%, and Adjusted EBITDA of $12–14 million. The company highlighted expanded reimbursement, new clinical indications under development, and minority investments in mental health providers as additional growth drivers.
BrainsWay Ltd. reported strong Q1 2026 growth and profitability while emphasizing its shift to a high-margin recurring revenue model. Q1 2026 revenue rose 35% year over year to about $15.5 million, with net income more than doubling to roughly $2.3 million and Adjusted EBITDA up 117% to about $2.8 million.
The company shipped a record 117 Deep TMS systems in the quarter, expanding its installed base to roughly 1,820 systems and supporting an ARR-focused lease and pay-per-use model. Remaining performance obligations reached about $75 million and cash was $58 million as of March 31, 2026, with no debt.
BrainsWay reiterated full-year 2026 guidance for revenue of $66–68 million, operating income margin of 13–14%, and Adjusted EBITDA of $12–14 million. The company highlighted expanded reimbursement, new clinical indications under development, and minority investments in mental health providers as additional growth drivers.
BrainsWay Ltd. ownership disclosure: Masters Capital Management, LLC and Michael Masters report beneficial ownership of 1,500,000 Ordinary Shares of BrainsWay Ltd., representing 3.8% of the class. The percent is calculated using 39,165,806 Ordinary Shares outstanding as of December 31, 2025.
The filing is an amendment (Schedule 13G/A, Amendment No. 2) and lists shared voting and dispositive power of 1,500,000 shares held directly by Masters Funds. Signatures are by Michael Masters dated 05/13/2026.
BrainsWay Ltd. ownership disclosure: Masters Capital Management, LLC and Michael Masters report beneficial ownership of 1,500,000 Ordinary Shares of BrainsWay Ltd., representing 3.8% of the class. The percent is calculated using 39,165,806 Ordinary Shares outstanding as of December 31, 2025.
The filing is an amendment (Schedule 13G/A, Amendment No. 2) and lists shared voting and dispositive power of 1,500,000 shares held directly by Masters Funds. Signatures are by Michael Masters dated 05/13/2026.
BrainsWay Ltd. reported strong first quarter 2026 results, with revenue up 35% year-over-year to $15.5 million and net income more than doubling to $2.3 million. Adjusted EBITDA rose 117% to $2.8 million, reflecting improved profitability on higher sales.
Remaining performance obligations grew 25% to about $75 million, and the company shipped a record 117 Deep TMS systems, lifting the installed base to roughly 1,820 systems. Management reiterated full-year 2026 guidance for revenue of $66–$68 million, operating income of 13–14% of revenue, and Adjusted EBITDA of $12–$14 million, and ended the quarter with $58.9 million in cash and restricted cash.
BrainsWay Ltd. reported strong first quarter 2026 results, with revenue up 35% year-over-year to $15.5 million and net income more than doubling to $2.3 million. Adjusted EBITDA rose 117% to $2.8 million, reflecting improved profitability on higher sales.
Remaining performance obligations grew 25% to about $75 million, and the company shipped a record 117 Deep TMS systems, lifting the installed base to roughly 1,820 systems. Management reiterated full-year 2026 guidance for revenue of $66–$68 million, operating income of 13–14% of revenue, and Adjusted EBITDA of $12–$14 million, and ended the quarter with $58.9 million in cash and restricted cash.
BRAINSWAY LTD. amendment to a Schedule 13G/A reports that Harel Insurance Investments & Financial Services Ltd. beneficially owns 2,677,117 Ordinary Shares (reported here as Ordinary Shares) representing 6.8% of the class based on 39,165,806 Ordinary Shares outstanding as of December 31, 2025. The filing breaks down holdings between client/managed accounts and a small proprietary position and is signed by a company officer on 05/04/2026.
BRAINSWAY LTD. amendment to a Schedule 13G/A reports that Harel Insurance Investments & Financial Services Ltd. beneficially owns 2,677,117 Ordinary Shares (reported here as Ordinary Shares) representing 6.8% of the class based on 39,165,806 Ordinary Shares outstanding as of December 31, 2025. The filing breaks down holdings between client/managed accounts and a small proprietary position and is signed by a company officer on 05/04/2026.
BrainsWay Ltd. files its annual report describing a shift to profitability, detailed risk factors and capital needs. The company reports net income of $2.9 million for 2024 and $7.5 million for 2025, but still has an accumulated deficit of $90.8 million as of December 31, 2025.
BrainsWay depends on its Deep TMS systems for depression, OCD and smoking addiction, and highlights risks around physician adoption, competition from other TMS and drug therapies, and reimbursement hurdles. The report also notes supply-chain and geopolitical risks tied to its Israeli manufacturing base and reliance on select large clinic networks.
As of December 31, 2025, BrainsWay had 39,165,806 ordinary shares outstanding and remains reliant on external financing, including a November 2024 private placement, to support growth, clinical trials and further regulatory expansion for Deep TMS.
BrainsWay Ltd. files its annual report describing a shift to profitability, detailed risk factors and capital needs. The company reports net income of $2.9 million for 2024 and $7.5 million for 2025, but still has an accumulated deficit of $90.8 million as of December 31, 2025.
BrainsWay depends on its Deep TMS systems for depression, OCD and smoking addiction, and highlights risks around physician adoption, competition from other TMS and drug therapies, and reimbursement hurdles. The report also notes supply-chain and geopolitical risks tied to its Israeli manufacturing base and reliance on select large clinic networks.
As of December 31, 2025, BrainsWay had 39,165,806 ordinary shares outstanding and remains reliant on external financing, including a November 2024 private placement, to support growth, clinical trials and further regulatory expansion for Deep TMS.
BrainsWay Ltd. furnished an update highlighting growing U.S. payer support for nurse practitioner‑administered Transcranial Magnetic Stimulation (TMS) therapy, including its Deep TMS™ platform. Optum Behavioral Health revised its TMS policy in late 2025 to let psychiatric mental health nurse practitioners order, supervise, and administer TMS in full‑practice states, covering approximately 34.8 million lives.
BrainsWay notes that other commercial insurers, several Medicare Administrative Contractors, the U.S. Department of Veterans Affairs, and TRICARE West have adopted similar approaches. The company believes broader acceptance of nurse practitioner‑delivered Deep TMS can ease psychiatrist shortages and improve access to non‑drug mental health treatments.
BrainsWay Ltd. furnished an update highlighting growing U.S. payer support for nurse practitioner‑administered Transcranial Magnetic Stimulation (TMS) therapy, including its Deep TMS™ platform. Optum Behavioral Health revised its TMS policy in late 2025 to let psychiatric mental health nurse practitioners order, supervise, and administer TMS in full‑practice states, covering approximately 34.8 million lives.
BrainsWay notes that other commercial insurers, several Medicare Administrative Contractors, the U.S. Department of Veterans Affairs, and TRICARE West have adopted similar approaches. The company believes broader acceptance of nurse practitioner‑delivered Deep TMS can ease psychiatrist shortages and improve access to non‑drug mental health treatments.
Brainsway Ltd. disclosure: MEITAV Investment House Ltd. reports shared voting and dispositive power over 2,099,637 American Depositary Shares (ADS) representing 5.24% of ordinary shares based on 40,033,028 ordinary shares outstanding as of March 31, 2026.
The filing states the reported ADS are held across subsidiaries and client accounts: 408,408 ordinary shares (1.02%) by Meitav Tachlit Mutual Funds Ltd. and 1,691,229 ordinary shares (4.22%) by Meitav Provident Funds & Pension Ltd. Voting and investment decisions are described as made by each subsidiary under independent management.
Brainsway Ltd. disclosure: MEITAV Investment House Ltd. reports shared voting and dispositive power over 2,099,637 American Depositary Shares (ADS) representing 5.24% of ordinary shares based on 40,033,028 ordinary shares outstanding as of March 31, 2026.
The filing states the reported ADS are held across subsidiaries and client accounts: 408,408 ordinary shares (1.02%) by Meitav Tachlit Mutual Funds Ltd. and 1,691,229 ordinary shares (4.22%) by Meitav Provident Funds & Pension Ltd. Voting and investment decisions are described as made by each subsidiary under independent management.